Proteros biostructures GmbH ("Proteros") today announced that the company entered into a Lead Discovery Collaboration with Priaxon AG to jointly develop lead compounds for high value protein-protein interaction (PPI) drug targets.
The combination of Proteros' structure guided discovery with Priaxon's PPI-directed drug discovery platforms will be focused on the identification of novel small molecule modulators for PPI targets. As part of this collaboration, Proteros will apply its integrated Lead Discovery expertise and technologies in the field of structural biology, biophysics and screening. Priaxon will apply its proprietary drug discovery platform Priaxplore®, which combines a proprietary PPI focused chemical space with special tailor made chemoinformatic methods for the identification of potential PPI modulators.
"The combination of Proteros' strength in structural biology and biophysics with the Priaxon's PPI focused drug discovery platform Priaxplore® forms an excellent basis to make PPI targets of high interest addressable by small molecule modulators" said Dr. Juergen Kolb, CEO of Priaxon.
Dr. Torsten Neuefeind, CEO of Proteros, stated: "We are very pleased to have formed this relationship with Priaxon. Both companies have complementary platforms as well as an established track-record. PPIs are a big challenge in drug discovery and the use of structural information, computational chemistry and Priaxons' validated chemistry approach allows us to respond to the industry demand for such targets in a unique manner".